Linagliptin

Jeneng Kimia:

8-[(3R)-3-aminopiperidin-1-yl]-7-(nanging-2-yn-1-yl)-3- metil-1-[(4-methylquinazolin-2-yl)metil]-3 ,7-dihydro-1H-purine-2,6-dione

Kode SMILES:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 = O

Kode Inchi:

InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33(23(21 )34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2 ,1-3H3/t17-/m1/s1

Kunci InChi:

LTXREWYXXSTFRX-QGZVFWFLSA-N

tembung kunci:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Kelarutan:Larut ing DMSO

Panyimpenan:0 - 4°C kanggo jangka cendhak (dina nganti minggu), utawa -20°C kanggo jangka panjang (sasi).

katrangan:

Linagliptin, uga dikenal minangka BI-1356, minangka inhibitor DPP-4 sing dikembangake dening Boehringer Ingelheim kanggo perawatan diabetes tipe II. Linagliptin (sapisan saben dina) disetujoni dening FDA AS tanggal 2 Mei 2011 kanggo perawatan diabetes tipe II. Iki dipasarake dening Boehringer Ingelheim lan Lilly.

Sasaran: DPP-4